DoxyPEP Cuts Syphilis Risk 73%-80% in Gay, Bisexual Men and Transgender Women
Updated
Updated · European AIDS Treatment Group · May 19
DoxyPEP Cuts Syphilis Risk 73%-80% in Gay, Bisexual Men and Transgender Women
2 articles · Updated · European AIDS Treatment Group · May 19
Randomized trials in San Francisco and France found doxycycline taken shortly after sex reduced syphilis risk by 73% to 80% in gay and bisexual men and transgender women who have sex with men.
The studies also showed lower chlamydia risk, and gonorrhea infections fell where the bacteria remained susceptible to doxycycline.
That broad STI reduction has driven wider doxyPEP use among gbMSM, transgender women and other groups at elevated risk of sexually transmitted infections.
A new pill prevents STIs, so why are at-risk groups getting it without a doctor?
As this new STI shield fails against gonorrhea, what is the next move for sexual health?
Is the new 'morning-after pill' for STIs already creating an untreatable superbug?
DoxyPEP in 2025: CDC Guidelines, 50–80% STI Reduction, and the Challenge of Antibiotic Resistance
Overview
Doxycycline Postexposure Prophylaxis (DoxyPEP) is a major public health advance for preventing bacterial sexually transmitted infections (STIs) as of late 2025. By taking a dose of doxycycline within three days after unprotected sex, individuals can reduce their risk of acquiring certain STIs. The Centers for Disease Control and Prevention (CDC) has issued clinical guidance, giving healthcare providers a clear framework to implement DoxyPEP effectively. DoxyPEP is used as a preventative measure, not as a treatment for existing infections, and people using it are advised to continue regular healthcare visits for ongoing screening and care.